Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct 1;27(10):e827-e828.
doi: 10.1093/oncolo/oyac171.

In Reply

Mario E Lacouture  1   2 , Anisha B Patel  3 , Jonathan E Rosenberg  1   2 , Peter H O'Donnell  4
Affiliations
Editorial

In Reply

Mario E Lacouture et al. Oncologist. .

Abstract

This letter to the editor responds to remarks on a recently published article about dermatologic events associated with enfortumab vedotin and agrees that education on the prevention and management of such events should be a priority.

PubMed Disclaimer

Comment in

Comment on

References

    1. Ingen-Housz-Oro S, Thibault C, Sohier P, Dupin N.. Regarding “Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate Enfortumab Vedotin”. Oncologist. 2022;27:e825-e826. - PMC - PubMed
    1. Lacouture ME, Patel AB, Rosenberg JE, O’Donnell PH.. Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist. 2022;27(3):e223-e232. 10.1093/oncolo/oyac001. - DOI - PMC - PubMed
    1. Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O.. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):1996-2011. - PubMed
    1. Weinkle A, Pettit C, Jani Aet al. . Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation - A retrospective chart review. J Am Acad Dermatol. 2019;81(3):749-757. - PubMed
    1. Chen CB, Wu MY, Ng CY, Lu CWet al. . Severe cutaneous adverse reactions induce by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018;10:1259-1273. - PMC - PubMed